-+ 0.00%
-+ 0.00%
-+ 0.00%

Novartis Announces Its Data From Phase III NATALEE Study Demonstrates Kisqali Eliminates Risk Of Death By ~20% In Patients With Stage II And III HR+/Her2- Early Breast Cancer

Benzinga·10/23/2026 11:55:18

https://www.novartis.com/news/media-releases/kisqali-shows-clinically-meaningful-overall-survival-broadest-hrher2-early-breast-cancer-population-high-risk-recurrence